Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Nivolumab (Primary) ; Veliparib (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours; T cell lymphoma
- Focus Adverse reactions
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.
- 19 Apr 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jun 2017.
- 03 Mar 2017 New trial record